iQ&A Interactive Cardiovascular Intelligence Zone for Comprehensive Thrombosis Management
The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes national and international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.
To ensure that the educational content of iQ&A programs will address practice gaps in clinical medicine, improve patient outcomes, and positively guide clinical practice strategies, international experts, usually in a roundtable format, will respond to questions submitted and/or generated by practitioners at CME mega-symposia, national congress, association meetings, or as part of on-line, enduring CME programs.
Questions reflecting the clinical needs of practitioners are then answered, analyzed, and discussed by international experts, who provide evidence-based and clinically relevant guidance that is independently of commercial sources or the program sponsor.

The iQ&A platform stresses:

  • Needs assessment-driven CME content
  • Evidence-based analysis
  • Expert-based guidance and consultation
  • Compliance adherence
  • Independence of content generation
  • Landmark trials
  • Association-generated practice management guidelines
  • Quality of care improvement
  • Practice gap improvement

Program Medium
Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period December 17, 2013 through December 17, 2015, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 81 segments, totaling 3 hours and 15 minutes, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

3.25 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in thrombosis management.

Release Date

December 17, 2013

Expiration Date

December 17, 2015

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with or at risk for thrombosis.

This constituency of HCPs shall include the following audience:

  • Cardiologists
  • Thrombosis medicine specialists
  • Neurologists
  • Preventive medicine specialists
  • Cardiology department program directors
  • Clinical geneticists
  • Clinical cardiovascular pharmacists
  • Related specialists

Registration

Participation in this iQ&A interactive Medical Intelligence Zone for Comprehensive Thrombosis Management is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from Daiichi Sankyo, Inc.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Samuel Z. Goldhaber, MD
Program Co-Chairman and Moderator
Professor of Medicine
Harvard Medical School
President, North American Thrombosis Forum
Director, Thrombosis Research Group
Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts

Consultant: Baxter, Boehringer Ingelheim, Bristol Myers Squibb,
Daiichi Sankyo, Eisai, Merck, Pfizer, Portola, Sanofi Aventis
Research Support: Daiichi Sankyo, Eisai, EKOS, J&J, Sanofi Aventis


Christian T. Ruff, MD, MPH
Program Co-Chairman
Associate Physician
Cardiovascular Division
Brigham and Women’s Hospital
Instructor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Board: Daiichi Sankyo and Boehringer Ingelheim
Grant/Research Support: Daiichi Sankyo


Dan Atar, MD, PhD
Professor of Medicine
Department of Cardiology
Oslo University Hospital Ullevaal
Oslo, Norway

Speaker and Consultant: BMS/Pfizer, Bayer, Boehringer-Ingelheim, Merck, sanofi-aventis


Richard Becker, MD
Mabel Stearns Stonehill Chair of Cardiology
Director, University of Cincinnati Cardiovascular Institute (UCCVI)
Division of Cardiovascular Health and Disease
Director of the Cardiovascular Center of Excellence in Research
Chief of Cardiovascular Services at West Chester Hospital
Professor of Medicine
University of Cincinnati College of Medicine

Consultant: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Canyon Pharmaceuticals Group; Daiichi Sankyo, Inc.; Eli Lilly and Company; Merck & Co., Inc.; Momenta Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.; Regado Biosciences
Grant/Research Support: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Regado Biosciences



Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital
Heart and Vascular Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consultant: Arena, Astra Zeneca, Bristol-Myers Squibb, Cardax, Cogentus, Daiichi Sankyo, Eli Lilly, Eisai, Glaxo Smith Kline, Johnson & Johnson, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis, Schering Plough, Takeda, The Medicines Company, Vertex.
Principal Investigator for several potentially related studies. His institution has received funding from Bristol Myers Squibb, Eisai, Ethicon, Heartscape, sanofi-aventis, The Medicines Company


Raffaele De Caterina, MD, PhD
Professor of Cardiology
Chairman of Cardiology and Director
Postgraduate School of Cardiology
‘G d’Annunzio’ University in Chieti
Chiete, Italy

Consultant and speaker fees: AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Lilly
Grants/Research Support: AstraZeneca and Boehringer-Ingelheim


James Douketis, MD
Professor
Division of Hematology and Thromboembolism
Associate Director
Clinical Teaching Unit, St. Joseph's Hospital
Hamilton, Ontario
Canada

Consultant: Boehringer Ingelheim, Bristol-Myers Squibb, Bayer


John Eikelboom, MD
Associate Professor of Medicine
McMaster University
Canada Research Chair in Cardiovascular Medicine
Ontario, Canada

Speaker: AstraZeneca, Boehringer Ingelheim, and sanofi-aventis.


Robert P. Giugliano, MD
Associate Physician, Cardiovascular Division
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Grant/Research Support: Daiichi Sankyo
Consultant: Johnson & Johnson


Andreas Goette, MD
Professor of Medicine
Chairman of Cardiology
St. Vincent Hospital of Paderborn
Paderborn, Germany

Consultant: Merck & Co., Inc.; sanofi-aventis
Speaker: Merck & Co., Inc.; sanofi-aventis


Stefan Hohnloser, MD
Director, Department of Clinical Electrophysiology

J. W. Goethe University
Frankfurt, Germany

Consultant: sanofi-aventis, Boehringer Ingelheim, St. Jude Medical, Cardiome Pharma Corp., ARYx Therapeutics, Bristol-Myers Squibb
Speaker/Speaker’s Bureau: sanofi-aventis, Boehringer Ingelheim, St. Jude Medical, Cardiome Pharma Corp., ARYx Therapeutics, Bristol-Myers Squibb
Grant/Research Support: sanofi-aventis, St. Jude Medical


Ajay Kakkar, MBBS, PhD, FRCS
Head of the Centre for Surgical Sciences
Barts and the London
Queen Mary's School of Medicine and Dentistry
Thrombosis Research Institute
London, UK

Consultant: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Co., Ltd.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sanofi
Grant/Research Support: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Co., Ltd.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sanofi

Jean Yves Le Heuzey, MD
Professor of Cardiology
René Descartes University Head of Arrhythmia Department
Georges Pompidou Européen Hospital
Paris, France

Research support/advisory boards: sanofi-aventis, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo


Gregory Lip, MD
Consultant Cardiologist
Professor of Cardiovascular Medicine
Director, Haemostasis Thrombosis & Vascular Biology Unit
University of Birmingham Centre for Cardiovascular Sciences
City Hospital, Birmingham
England

Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis; Bayer HealthCare Pharmaceuticals; Merck & Co., Inc.; Astellas Pharma, Inc.; Portola Pharmaceuticals, Inc.; BIOTRONIK, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Pfizer Inc
Speaker or a member of a speakers bureau: Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company; Pfizer Inc.


Alexander G. G. Turpie, MD, FRCP, FACP, FACC, FRCPC
Professor of Medicine, Emeritus
Department of Medicine
Hamilton Health Sciences-General Hospital
Hamilton, Ontario
Canada

Consultant: Bayer Pharma, Janssen, Astellas, Takeda
Speaker’s Bureau: Janssen, Boehringer-Ingelheim

Freek Verheught, MD
Professor of Cardiology
Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands

Consultant: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company
Speaker: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company


Jeff Weitz, MD
Professor of Medicine and Biochemistry
McMaster University
Canada Research Chair in Thrombosis Heart and Stroke Foundation
J.F. Mustard Chair in Cardiovascular Research
Hamilton, Ontario
Canada

Advisor or consultant: Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis; Daiichi Sankyo, Inc.; Takeda Pharmaceuticals North America, Inc.; Bayer HealthCare Pharmaceuticals; Pfizer Inc.; Portola Pharmaceuticals, Inc.; Merck & Co., Inc.

Program Faculty and Disclosure

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:
  • Balance the benefit-to-risk equation for oral anticoagulation-based management of SPAF and VTE, with a focus on both reducing the risk of thrombosis (stroke or VTE) and mitigating the risks of bleeding, including ICH and other possible bleeding complications of anticoagulation based management;
  • Details the results of the Hokusai-VTE Trial, with a focus on the safety and efficacy of factor Xa-mediated therapy for treatment of PE and DVT, including usual and renal dosing considerations, subset results in high risk patients with PE (including those with RV ventricular failure and elevated BNP), and bleeding complications compared to warfarin;
  • Understand the clinical and translational implications of the Hokusai-VTE Trial, with a focus on the safety and efficacy of factor Xa-mediated therapy for treatment of PE and DVT, with a focus on how to translate the results of this trial to the front lines of VTE treatment;
  • Detail the results of the ENGAGE Trial, with a focus on the safety and efficacy of factor Xa-mediated therapy for stroke prevention in AF, including outcomes with various dosing regimens, subset results in patients with variable CHADS2 and CHA2DS2-VASc and HAS-BLED –risk scores, age, and co-morbid conditions;
  • Understand the translational and practical implications of the ENGAGE Trial, with a focus on the safety and efficacy of factor Xa-mediated therapy for stroke prevention in AF, including outcomes with various dosing regimens, subset results in patients with variable CHADS2 and CHA2DS2-VASc and HAS-BLED – risk scores, age, and co-morbid conditions.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2013 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC